Molecular Analysis of 150 Lung Adenocarcinoma

• Conditions: Lung Adenocarcinoma
• Interventions: Genetic: Sequencing

• Registration Number: NCT02843711
• Lead Sponsor: Hospices Civils de Lyon

Brief Summary

LUNG-EST is a retrospective study including 152 patients who benefit from lung surgery during the years 2012 to 2013 at Hospices civils de Lyon and with a diagnosis of lung adenocarcinomas. For all patients, clinical data and histopathological data are available. The objective of this study is to characterize these lung adenocarcinomas by the LungCarta Panel using the mass spectrometry array Sequenom. This panel could identify 214 DNA mutations and/or frameshift insert/deletion among 26 oncogenes. Once included in the study, the adenocarcinomas are also included in a Tissue MicroArray (TMA) in order to perform immunohistochemical analysis. Immunohistochemical staining with innovative antibodies are correlated with clinical, histopathological and molecular data.

Our hypothesis is that this TMA could constitute a good tool to screen interesting protein's expression.

Detailed Description

Not available

Study Timeline

• Study Start: 2014-01
• Primary Completion: 2016-01
• Status Verified: 2016-07
• Study First Submitted: 2016-07-20
• Study First Submitted QC: 2016-07-21
• Last Update Submitted: 2016-07-21
• Study First Posted: 2016-07-26
• Last Update Posted: 2016-07-26
• Study Completion: 2017-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 152

Inclusion Criteria

• Adults
• lung adenocarcinoma
• Surgical specimen

Read More

Exclusion Criteria

• not adenocarcinoma subtype of lung cancer
• Tumour biopsy
• insufficient material for DNA extraction

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Adenocarcinoma	Sequencing	Tumour samples coming from patients harboring a lung adenocarcinoma diagnosed at the Hospices Civils de Lyon. Tumour samples are coming from lung surgery.

Primary Outcome Measures

Name	Time	Method
Genomic DNA Mutation	at diagnosis (Day 0)	Mutations identified by the LungCarta Panel (Sequenom) at the time of diagnosis. DNA was extracted from the lung surgical specimen.

Trial Locations

Locations (1)

Anatomie et cytologie pathologiques Groupement hospitalier Est, Institut de cancérologie des Hospices civils de Lyon,; 🇫🇷 Lyon, France